Andrew Foxley

AstraZeneca (United Kingdom) — United Kingdom

Medicine · Health Sciences

16h-index2.4kcitations73works2.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Breast Cancer Therapies(44), PI3K/AKT/mTOR signaling in cancer(39), PARP inhibition in cancer therapy(18), Protein Degradation and Inhibitors(15), Cancer Treatment and Pharmacology(13)

Publications73 total

Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial
Annals of Oncology·2025Open Access
CASE HISTORY: TRUQAP® (CAPIVASERTIB) WITH FULVESTRANT FOR THE TREATMENT OF HR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA/AKT1/PTEN-ALTERATIONS
Medicinal chemistry reviews·2025
Why PTEN Matters in Metastatic Hormone-Sensitive Prostate Cancer: Precision Medicine and Prognostic Value
2025Open Access
A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer
Future Oncology·2024· 5 citedOpen Access
LBA19 Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial
Annals of Oncology·2024· 8 citedOpen Access
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
New England Journal of Medicine·2023· 603 citedOpen Access
187O Capivasertib and fulvestrant for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Subgroup analyses from the phase III CAPItello-291 trial
ESMO Open·2023· 11 citedOpen Access
Supplementary Data from Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non–<i>BRCA1/2</i>-Mutant Cancers
2023Open Access
Data from Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non–<i>BRCA1/2</i>-Mutant Cancers
2023Open Access
Supplementary Data from Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non–<i>BRCA1/2</i>-Mutant Cancers
2023Open Access
Data from Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non–<i>BRCA1/2</i>-Mutant Cancers
2023Open Access
Supplementary Material from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i><sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer
2023Open Access
Data from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i><sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer
2023Open Access
Data from Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT)
2023Open Access
Data from Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT)
2023Open Access
Supplementary Table 4 from A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i>-Mutated Breast and Gynecologic Cancers
2023Open Access
Supplementary Material from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i><sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer
2023Open Access
Supplementary material from A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i>-Mutated Breast and Gynecologic Cancers
2023Open Access
Supplementary Data from Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT)
2023Open Access
Supplementary Figure 3 from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i><sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Gaia Schiavon(34), Justin P.O. Lindemann(29), Martin Pass(22), Udai Banerji(22), Paul Rugman(20), Elza C. de Bruin(16), Mafalda Oliveira(14), Nicholas C. Turner(13), Rhiannon Maudsley(13), Marie Cullberg(12), Sarat Chandarlapaty(11), José Baselga(11), Robert McEwen(10), David M. Hyman(10), Lillian M. Smyth(10), José Alejandro Pérez Fidalgo(10), Helen Ambrose(10), S.Y. Amy Cheung(10), Claire Corcoran(10), Sacha J. Howell(9)